Skip to main content

Table 1 Demographic and clinical characteristics of study subjects

From: Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients

 

Responder

Resistant

Age (year (mean ± SD))

50.27 ± 12.72

46.39 ± 11.27

Gender (number (%))

Male: 21 (48%)

Male: 14 (50%)

 

Female: 23 (52%)

Female: 14 (50%)

WBC (× 103 cell/μL)

Primary: 125.53 ± 241.75

Primary: 820.97 ± 773.31

 

Secondary: 810.9 ± 765.05

Secondary: 774.53 ± 566.89

Plt (× 105/μL)

Primary: 2.5070 ± 1.7844

Primary: 2.0548 ± 1.2716

 

Secondary: 2.5196 ± 1.4656

Secondary: 1.9325 ± 9.2211

Hb (g/dL)

Primary: 12.6 ± 2.39

Primary: 12.9 ± 1.76

 

Secondary: 12.6 ± 2.26

Secondary: 12.8 ± 1.60